---
title: "Defining type 2 diabetes polygenic risk scores through colocalization and network-based clustering of metabolic trait genetic associations"
description: |
  * **Core Principle**: This study partitioned the genetic heterogeneity of **Type 2 Diabetes (T2D)** using a novel **colocalization-first** approach followed by network-based clustering of T2D and **20 related metabolic traits** across 243 loci.
  * **Key Finding**: The method identified **five distinct T2D biological pathways** (Obesity, Lipodystrophic insulin resistance, Liver/lipid metabolism, Hepatic glucose metabolism, and Beta-cell dysfunction), successfully isolating genetically distinct disease mechanisms.
  * **Clinical Significance**: **Partitioned Polygenic Risk Scores (PRSs)** showed heterogeneous clinical associations in a validation cohort (n=21,742 T2D individuals); notably, the **Lipodystrophic insulin resistance PRS** and **Beta-cell dysfunction PRS** were causally associated with **lower BMI**, providing genetic validation for the clinically important **"lean diabetes"** sub-type.
  * **Methodological Advance**: By integrating colocalization and **Mendelian Randomization**, the framework provided stronger inferences on the **causality and directionality** of the genetic associations, which is essential for translating genetic discoveries into targeted T2D treatments.
date: last-modified
categories: [colocalization, disease subtyping, mendelian randomization, pleiotropy, polygenic risk scores]
---
**PubMed:** [38200577](https://pubmed.ncbi.nlm.nih.gov/38200577/)
**DOI:** [10.1186/s13073-023-01255-7](http://dx.doi.org/10.1186/s13073-023-01255-7)
**Overview generated by:** Gemini 2.5 Flash, 26/11/2025

## Key Findings: Dissecting T2D Heterogeneity via Pleiotropy

This study addresses the profound genetic and clinical heterogeneity of **Type 2 Diabetes (T2D)** by developing a refined framework to partition T2D-associated genetic variants into distinct biological pathways. The goal is to move beyond a single, monolithic T2D diagnosis toward stratified risk prediction and targeted therapeutic strategies. The method leverages the **pleiotropic** nature of genetic variants—their influence on multiple related traits—to define distinct mechanisms of T2D pathogenesis.

### Colocalization-First Partitioning and Clustering

The authors improved upon previous clustering approaches by integrating rigorous statistical checks for shared causality, enhancing the mechanistic interpretability of the resulting risk scores.

1.  **Colocalization Analysis**: They applied **colocalization** analysis between T2D and **20 related metabolic traits** (selected based on established risk factors and genetic correlation) across **243 T2D loci**. This step robustly identified **146 T2D loci** where the T2D association was likely caused by the *same causal variant* as the associated metabolic trait.
2.  **Network-Based Clustering**: A **network-based unsupervised hierarchical clustering** approach was then performed using the colocalized variant-trait associations. This successfully grouped the T2D risk loci into **five distinct clusters**, each representing a unique, interconnected set of T2D and metabolic risk factors.
3.  **Causality Check (Mendelian Randomization)**: The study explicitly assessed the causality and directionality of the variant-trait associations using the **Mendelian randomization (MR) Steiger's Z-test**. This confirmed that the genetic associations identified in the clusters were largely causal for the corresponding metabolic phenotypes. 

### Five Distinct T2D Pathophysiological Clusters

The five identified genetic clusters, which align with distinct T2D pathophysiologies, are:
1.  **Obesity** (High BMI-T2D risk)
2.  **Lipodystrophic insulin resistance** (T2D risk associated with fat distribution/dysfunction)
3.  **Liver and lipid metabolism**
4.  **Hepatic glucose metabolism**
5.  **Beta-cell dysfunction** (Impaired insulin secretion)

### Heterogeneous Clinical Profiles and "Lean Diabetes"

**Partitioned Polygenic Risk Scores (PRSs)** were generated for each cluster and externally validated in **21,742 individuals with T2D** across three independent cohorts, demonstrating unique associations with metabolic and clinical outcomes:

* **Opposite BMI Associations**: The **Obesity PRS** was strongly associated with a **higher BMI**, as expected. Critically, the **Lipodystrophic insulin resistance PRS** and **Beta-cell dysfunction PRS** were both associated with **lower BMI**.
* **Support for Lean Diabetes**: The MR Steiger analysis provided causal evidence that increased T2D risk in the lipodystrophic insulin resistance and beta-cell dysfunction pathways was **causally associated with lower BMI**. This provides a genetic foundation for the **"lean diabetes"** or non-obese T2D sub-type, where risk is driven by dysfunctional fat/insulin-secretion rather than overall fat mass.
* **Comorbidity Stratification**: The **Lipodystrophic insulin resistance PRS** was uniquely and specifically associated with a **higher odds of chronic kidney disease (CKD)** (Odds Ratio 1.29), suggesting that individuals whose T2D risk is driven by this pathway may require specific monitoring and intervention for renal complications.

### Conclusion

The colocalization-first, network-based clustering methodology successfully and robustly partitioned the genetic heterogeneity underlying T2D. The resulting pathway-specific PRSs provide valuable tools for risk stratification, sub-type identification, and the development of targeted therapies based on an individual's distinct genetic mechanism of disease.